Related Experiment Video

Updated: Aug 8, 2026

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

Fine tuning of PPAR ligands for type 2 diabetes and metabolic syndrome

Uma Ramachandran1, Rakesh Kumar, Amit Mittal

  • 1Department of Pharmaceutical Technology, National Institute of Pharmaceutical Education and Research, Sector 67, S.A.S. Nagar, Punjab 160 062, India. umaram54@yahoo.com

Mini Reviews in Medicinal Chemistry
|May 25, 2006
PubMed

Insights

New agents targeting nuclear hormone receptors, peroxisome proliferator activated receptors (PPARs), offer exciting therapeutic potential for type 2 diabetes mellitus (T2DM). These compounds aim to improve glucose and lipid homeostasis, addressing key risk factors for cardiovascular complications.

Area of Science:

  • Medicinal Chemistry
  • Endocrinology
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) is a widespread chronic condition with significant cardiovascular implications.
  • Hyperlipidemia, obesity, and insulin resistance are critical independent risk factors for coronary heart disease and macrovascular complications in diabetic patients.
  • Peroxisome proliferator activated receptors (PPARs) and their subtypes (alpha, gamma, delta/beta) are identified as key regulators of lipid, glucose, and energy metabolism.

Purpose of the Study:

  • To review potent agonists, dual agonists, pan agonists, and selective modulators (SPPARMs) of PPARs from a medicinal chemistry perspective.
  • To explore novel therapeutic agents for T2DM and associated metabolic disorders.
  • To highlight compounds targeting PPARs for improved insulin sensitivity and lipid profile management.

Main Methods:

  • Literature review of chemical compounds targeting PPARs.
  • Analysis of PPAR agonists, dual agonists, pan agonists, SPPARMs, and antagonists.
  • Focus on chemical structures and mechanisms of action.

Main Results:

  • Identification of highly potent PPARgamma agonists.
  • Characterization of PPARalpha/gamma dual agonists and PPAR pan agonists.
  • Discussion of alternative PPAR ligands including partial agonists and selective modulators (SPPARMs) and antagonists.

Conclusions:

  • PPAR-targeting agents represent a promising avenue for T2DM therapy.
  • Compounds modulating PPAR activity can simultaneously address insulin resistance and hyperlipidemia.
  • Further development of PPAR ligands offers potential for improved management of metabolic disorders and cardiovascular risk.

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...